CRMD — CorMedix Cashflow Statement
0.000.00%
Last trade - 00:00- $593.15m
- $541.47m
- $43.47m
- 38
- 13
- 96
- 47
Annual cashflow statement for CorMedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22 | -28.2 | -29.7 | -46.3 | -17.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.56 | 5.16 | 4.19 | 5.63 | 6.41 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.63 | 1.84 | 1.07 | 2.23 | -39.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -22 | -21.2 | -24.4 | -38.4 | -50.6 |
| Capital Expenditures | -0.113 | -1.43 | -0.219 | -0.327 | -0.116 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 7.54 | -7.71 | -3.49 | -16.7 | 21.3 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 7.43 | -9.13 | -3.71 | -17.1 | 21.2 |
| Financing Cash Flow Items | 0 | — | — | -0.198 | -0.29 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 40.1 | 41.8 | 17.9 | 55.9 | 26.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 25.6 | 11.5 | -10.2 | 0.448 | -3.07 |